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1.25 hospitalizations. Diagnostic tests were also more frequent (rectosigmoidoscopy: 
49.3%; abdominal echography: 43.6%) except thyroid function (70.0%). The annual 
cost of second line was € 2,114 [1,509;2,819] versus € 2,920 [2,072;3,917] after second 
line failure. Hospitalizations accounted for about 75% of the costs. ConClusions: 
IBS with constipation leads to significant resource use and high costs certainly in 
case of second line treatment failure.
Gastrointestinal DisorDers – Patient-reported outcomes & Patient  
Preference studies
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objeCtives: Using patient-reported and observer-reported outcome measures to 
assess symptoms in children is challenging. While the child is arguably the most 
‘valid’ reporter, parents may provide more reliable responses. Our aim was to 
assess the agreement in child and parent ratings of CC/IBS-C symptoms collected 
through an electronic daily diary (eDiary). Methods: Separate child and parent 
eDiaries were developed to assess CC/IBS-C symptoms based on concept elicita-
tion interviews with 64 children and 75 parents. The eDiaries were completed by 
36 children (aged 6-11) and 30 parents for 5-9 days prior to cognitive debriefing 
interviews. eDiary data were compared for five symptoms: abdominal pain, bowel 
movement (BM) frequency, stool form/consistency, straining and rectal pain during 
defecation. Results: There were moderate to high levels of agreement (children/
parents selecting the same level of response on a given day) for all items, including 
66.9% agreement for BM frequency; 70.2% for stool form and 72.5% for rectal pain. 
Children’s reports of their ‘tummy hurting’ were consistent with parents seeing 
their child holding his/her tummy (68.5% agreement) and parents being told by the 
child that his/her tummy hurt (76.4% agreement). Children’s reports of straining 
were consistent with parents observing their child making a face (60.4% agree-
ment) and hearing their child grunt (52.3% agreement) during defecation. Across 
all symptoms, agreement was higher for 6-8 year old children and their parents 
(mean 76.9% agreement) compared to 9-11 year old children and their parents (mean 
58.4%). ConClusions: The results present evidence of moderate to strong agree-
ment between children’s and parents’ reports of core CC/IBS-C symptoms. Lower 
levels of agreement in ratings amongst 9-11 year old children and their parents may 
be due to parents being less aware of their child’s symptoms.
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objeCtives: Fatigue is usually defined as a feeling of exhaustion, lack of energy 
or tiredness and affects many aspects of daily living. Crohn’s Disease (CD) is often 
associated with severe fatigue. The Fatigue Impact Scale (FIS) was developed to 
determine the mental and physical impacts of fatigue. It has been simplified and 
shortened to 22 items and shown by Rasch analysis to be unidimensional. This 
version is called the U-FIS. The study was designed to determine the validity of the 
U-FIS when used with CD patients. Methods: CD patients were asked to com-
plete the U-FIS and a subset of respondents completed it again two weeks later to 
assess test-retest reliability. Rasch analysis was applied to U-FIS data to determine 
unidimensionality. Construct validity was further assessed by relating scores on 
the U-FIS to those on the Crohn’s Life Impact Scale (CLIQ) and the Nottingham 
Health Profile (NHP). Results: A total of 158 CD patients (36.1% female; aged 16-79 
years (mean: 42.4; SD 15.0)) completed the U-FIS, with 103 completing it a second 
time. Overall fit to the Rasch model was confirmed (p = 0.61) and no items misfit. 
Internal consistency (0.98) and reproducibility (test-retest reliability = 0.88) for the 
U-FIS were good. U-FIS scores correlated 0.79 with those on the CLIQ indicating the 
importance of fatigue to quality of life. U-FIS scores were also related as expected 
with NHP section scores. ConClusions: The U-FIS is a reliable and valid instru-
ment for measuring fatigue in Crohn’s Disease. These findings replicate those found 
with the use of the measure with patients who have Multiple Sclerosis. The U-FIS 
is valuable as it provides a holistic index of the impact of fatigue from the patient’s 
perspective. The measure may prove valuable for use with patients who have a wide 
variety of chronic conditions.
PGi41
ValiDation of the Crohn’s life imPaCt Questionnaire (CliQ), the first 
Patient-rePorteD outCome measure sPeCifiC to aDults with Crohn’s 
Disease
Wilburn J.1, McKenna S.1, Twiss J.1, Kemp K.2, Campbell S.2
1Galen Research Ltd., Manchester, UK, 2Manchester Royal Infirmary, Manchester, UK
objeCtives: The study was designed to identify the final CLIQ – the first patient-
reported outcome measure specific to adults with Crohn’s Disease (CD) and deter-
mine its unidimensionality, reproducibility and construct validity. The measure has 
two scales; Activity limitations and needs-based Quality of Life (QoL). Methods: 
CD patients were sent a package consisting of the CLIQ, the Nottingham Health 
Profile (NHP), the Unidimensional Fatigue Impact Scale (U-FIS) and a demographic 
questionnaire. A subset of respondents received a second questionnaire package 
2 weeks later. Rasch analysis was applied to responses for item reduction and 
assessment of unidimensionality. Assessments of internal consistency, test-retest 
reliability and construct validity were also undertaken. Results: The CLIQ was 
completed by 273 CD patients (65.6% female; aged 16-79 years (mean: 43.9; SD 15.1). 
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objeCtives: To assess the cost-effectiveness of peginterferon α -2a and peginter-
feron α -2b in combination with ribavirin compared to best supportive care (BSC), for 
the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3 
to 17 years. Methods: A Markov state-transition economic model of chronic HCV 
in children and young people was developed that extrapolated the impact of sus-
tained virological response (SVR) on life expectancy, quality-adjusted life expectancy 
and lifetime costs. The model was adapted from one previously developed for adults. 
A systematic review was conducted of the clinical effectiveness of the treatments, 
and the health related quality of life for patients with hepatitis C. Uncertainty was 
explored through probabilistic and deterministic sensitivity analyses. Results: 
Seven studies were identified that were relatively small and of generally poor qual-
ity. Estimates of SVR were similar for peginterferon α -2a (60%) and peginterferon 
α -2b (58%), whilst the SVR for no treatment was assumed to be zero. From this 
model, peginterferon alfa (α -2a or α -2b) in combination with ribavirin was more 
effective and cheaper than BSC. Sensitivity analyses suggest that the results were 
generally robust to all changes to the structural assumptions and input parameters. 
The model results were most sensitive to changes to the discount rate, time hori-
zon, SVR and baseline fibrosis of the cohort. ConClusions: Treatment of children 
and young people with peginterferon alfa (α -2a or α -2b) and ribavirin may be an 
effective therapy. Peginterferon alfa (α -2a or α -2b) in combination with ribavirin is 
cost-effective compared with BSC. However, the available evidence is of poor quality. 
The views expressed in this paper are those of the authors and do not necessarily 
represent the views or policies of the UK HTA programme or Department of Health.
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objeCtives: To estimate the cost-effectiveness in Romanian setting of triple ther-
apy with Telaprevir and Peginterferon/Ribavirin (TVR+PR) compared with PR alone 
in previously untreated patients with hepatitis C virus (HCV) infection from the 
third payer - National Health Insurance Agency (NHIA). Methods: We used the 
published data of efficacy from large international trials and published Markov 
models to estimate the cost-effectiveness of this new HCV serine protease inhibi-
tor (telaprevir) using the specific local cost and epidemiological data. The superior 
results shown by Jacobson IM et all in ADVANCE trial - (Telaprevir for previously 
untreated chronic hepatitis C virus infection) for telaprevir - 75% sustained virologic 
response compared with 44% for PR alone. The discount rate was 3% for both cost 
and efficacy. Cost were extracted from NIHA tarrifs, Minister of Health drugs price 
catalog and from previous published data. The reference patient was a 45-year-old 
male with chronic liver disease due to chronic HCV infection. Time horizon was set 
patient life time. The clinical outcomes and Utilities for all health states were taken 
from ADVANCE phase-3 trial. The comparator was Peginterferon 2alfa with ribavirin. 
The effectiveness was measured in quality-adjusted life years (QALY).The cost of 
secondary drug reactions were not included in the model. Results: Incremental 
cost effectiveness ratio (ICER) for telaprevir in combination with PR compared to PR 
alone was 23291 € /1 gained QALY. ConClusions: As in Romania HTA is only at the 
beginning, health authorities has to evaluate the most cost-effective strategy to fol-
low for treatment of patients with chronic hepatitis as ICER of telaprevir in combina-
tion with PR compared with PR alone is reaching or is above the level recommended 
by Word Health Organisation as upper threshold (3 GDP/capita – Romania’s GDP/
capita is 6200Euro). Further CUA should be performed, including for guided therapy 
and treatment designated to previous treated patients.
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objeCtives: Patients suffering from irritable bowel syndrome (IBS) with constipa-
tion (IBS-C) receive laxatives as first line therapy. In spite of these laxatives most 
of them experience failure. We aimed at describing the current management and 
its costs of Belgian IBS-C patients who failed first line treatment. Methods: A 
2-round Delphi panel was conducted including general practitioners (GP) and 
gastroenterologists. The type and frequency of medical resources used per year 
as second-line IBS-C therapy (consultations, exams/tests, drugs, hospitalizations) 
were collected, reflecting the expert’s own practice in the first round and find-
ing a Belgian consensus in the second round. Two patients’ profiles were defined: 
second line current management and third line management in case of second 
line failure. Unit costs (2012 INAMI/RIZIV tariffs) were assigned to the resources 
used to calculate a cost per patient-year and a range based on the distribution of 
experts’ answers. Results: Eleven experts participated (6 GPs/5 gastroenterolo-
gists). The drugs prescribed in second line were laxatives (71.4%, mainly osmotics), 
spasmolytics (72.2%), pain killers (11.5%) and antidepressants (6.0%). There were 
7.7 consultations per patient-year on average (GP: 5.3; specialists: 2.4). Emergency 
room visits occurred in 10.4% and diagnostic tests included thyroid function (79.1%), 
rectosigmoidoscopy (39.8%) and abdominal echography (36.8%). There were 0.97 IBS-
related admissions to hospital per patient-year. After a second line failure, resource 
use increased with more laxatives (75.5%), antidepressants (24.6%) and pain killers 
(17.3%), 11.6 consultations (GP: 7.5; specialist: 4.1), 14.5% emergency room visits and 
